STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Unitaid published a report finding that manufacturing costs for one HIV medication could rise by 15% if oil reaches $120 per barrel.
- The report attributes 85% of those higher manufacturing costs to petrochemical ingredients used in drug production.
- Julien Pouille, lead author and head of Unitaid's climate and health strategic team, argues that reducing reliance on petrochemical products would simultaneously stabilize medicine costs and benefit the climate.
- The report was timed to Unitaid's climate and health strategy and concerns about access risks as Middle East conflict drives oil prices upward.
- Pouille framed the work as identifying potential risks to medicine access for the populations Unitaid serves, rather than just a supply-chain analysis.
Why it matters: For patients in low- and middle-income countries reliant on affordable HIV treatment, even a 15% manufacturing cost increase could strain supply if oil hits $120. Pouille's prescription — decarbonizing pharmaceutical inputs rather than just weathering oil shocks — reframes medicine access as a climate resilience problem, not just a pricing one.
Ask SkimNews
